Zepbound 5 MG/0.5 ML pen 0.5ML
Ended Awarded Last action
- Contract number
- SPE2DR26F88LD
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $27,991
Award facts
- Contract value 100% obligated
- $27,991.41 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $27,991.41 firm fixed-price delivery order to AmerSourceBergen Drug Corp on January 8, 2026, for the supply of Zepbound 5 mg/0.5 mL pens with a completion date of January 9, 2026. This is a non-set-aside competitive award with performance at the contractor's Conshohocken, Pennsylvania facility. AmerSourceBergen Drug Corp, a subsidiary of parent company Cencora, Inc., is a major pharmaceutical distributor serving federal medical procurement needs, particularly for military and veteran healthcare systems. The company holds a significant Indefinite Delivery Contract with the DLA Troop Support Medical (designated SPE2DX) valued at $999,999,999.00 through December 2026, which serves as the overarching vehicle for this delivery order and enables the company to supply a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally.
Zepbound (tirzepatide) is a glucagon-like peptide-1 receptor agonist approved for weight management in adults with overweight or obesity. This delivery order represents a discrete procurement under the broader pharmaceutical prime vendor contract, reflecting the DLA's ongoing need to source specialty medications for military treatment facilities and other federal healthcare systems. The non-set-aside competitive award status and firm fixed pricing structure are consistent with AmerSourceBergen's track record of meeting federal procurement requirements through open competition across its extensive portfolio of pharmaceutical deliveries.
Quick answers
Who was awarded contract SPE2DR26F88LD?
SPE2DR26F88LD was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 8, 2026.
How much is contract SPE2DR26F88LD worth?
The government has obligated $27,991 on SPE2DR26F88LD.
Is contract SPE2DR26F88LD an order under another contract?
Yes. SPE2DR26F88LD is a delivery order under SPE2DR25D3010, an indefinite delivery contract.
Was contract SPE2DR26F88LD competed?
The extent of competition for SPE2DR26F88LD was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award